Home Bratislava Medical Journal 2022 Bratislava Medical Journal Vol.123, No.10, p.730–735, 2022

Journal info


Published Monthly, in English
Founded: 1919
ISSN 0006-9248
(E)ISSN 1336-0345

Impact factor 1.564


Aims and Scope
Editorial Info
Submission Guidelines

Select Journal

Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Bratislava Medical Journal Vol.123, No.10, p.730–735, 2022

Title: The impact of different induction immunosuppression protocols on patient survival, graft survival and acute graft rejection after kidney transplantation
Author: Matej VNUCAK, Karol GRANAK, Monika BELIANCINOVA, Igor GALA, Michaela CHRAPEKOVA, Andrea KOVACOVA, Luboslav BENA, Zuzana ZILINSKA, Ivana DEDINSKA

Abstract: OBJECTIVES: The aim of the study was to stratify the immunological risk based on the presence of risk factors using different induction immunosuppressive protocols.
BACKGROUND: The path to successful kidney transplantation reflects the accuracy of immunological risk assessment and choice of correct induction and maintenance of immunosuppression to avoid acute kidney rejection.
METHODS: We performed a multicentre prospective analysis consisting of patients after kidney transplantation with a 12-month follow-up.
RESULTS: In total, 152 kidney transplant recipients were included, of whom 100 were males (66.4 %). We divided patients according to the induction immunosuppression as follows: no induction (n = 19), induction with basiliximab (n = 60), and induction with ATG at cumulative doses of 3.5 mg/kg (n = 42) and 6 mg/kg (n = 31). In our study, we demonstrated a shorter survival of patients without induction immunosuppression. In the basiliximab group, the duration of dialysis ≥ 3 years (p = 0.0191), cold ischaemia time ≥ 1,020 minutes or expected delayed graft function (p < 0.0001) are independent risk factors for graft loss (p = 0.0097).
CONCLUSIONS: Risk of no induction immunosuppression significantly exceeds the risks associated with its administration and is desirable even in patients at low immunological risk. Induction immunosuppression should be tailored individually and thus differ from patient to patient (Tab. 6, Fig. 1, Ref. 15).

Keywords: kidney transplantation, induction immunosuppression, graft survival, patient survival, acute kidney rejection
Published online: 23-Jul-2022
Year: 2022, Volume: 123, Issue: 10 Page From: 730, Page To: 735

download file

© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.